76836 Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel RFA– 

OD–23–013 and RFA–OD–23–014— 

Understanding Chronic Conditions 

Understudied Among Women Special 

Emphasis Panel (SEP), November 20, 

2023, 10:00 a.m. to November 21, 2023, 

06:30 p.m., National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD, 20892 which was 

published in the Federal Register on 

October 27, 2023, 88 FR 73865 Doc 

2023–23748 

This meeting is being amended to 

change the Panel name to Center for 

Scientific Review Special Emphasis 

Panel RFA–OD–23–013 and RFA–OD– 

23–014—Understanding Chronic 

Conditions Understudied Among 

Women. The meeting is closed to the 

public. 

Dated: November 2, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–24579 Filed 11–6–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Amy F. Petrik, Ph.D. at 240–627–3721 

or amy.petrik@nih.gov. Licensing 

information may be obtained by 

communicating with the indicated 

licensing contact at the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD, 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Base-Covered HIV–1 Envelope 

Ectodomains and Their Use 

Description of Technology: 

Researchers at the Vaccine Research 

Center (‘‘VRC’’) of the National Institute 

of Allergy and Infectious Diseases 

(‘‘NAID’’) continue to pursue a safe and 

effective HIV–1 vaccine to combat the 

HIV–1/AIDS pandemic. 

To this end, researchers have 

engineered the soluble HIV–1 

ectodomain trimer so that it is stabilized 

in its prefusion conformation by 

artificial disulfides, helix-disrupting 

prolines, and other structure-based 

alterations. However, mice and nonhuman primates immunized with these 

engineered soluble HIV–1 trimers 

produced a significant (>90% in some 

cases) immune response to the exposed 

trimer base. 

VRC researchers further modified the 

engineered prefusion soluble HIV–1 

trimers by adding N-linked glycans to 

specific sites on the protein’s base to 

block this immunodominant surface. 

They found that these N-linked glycans 

did reduce production of nonneutralizing antibodies directed to the 

trimer base. These soluble, glycanmasked prefusion HIV–1 trimers are 

envisioned as being a part of a 

heterologous prime-boost vaccine 

regimen. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Vaccine for prevention of HIV–1 

infection 

• Therapeutic vaccine for treatment of 

HIV–1 infection 

Competitive Advantages: 

• Currently, no licensed HIV vaccine 

exists 

Development Stage: 

• Animal studies 

Inventors: Peter Kwong, John Mascola, 

Tongqing Zhou, Adam Olia, Reda Rawi, 

Yongping Yang, Cheng Cheng (all of 

NIAID). 

Publications: Olia, et al. (2023) 

Soluble prefusion-closed HIV-envelope 

trimers with glycan-covered bases. 

iScience 26, 107403, August 18, 2023. 

DOI: https://doi.org/10.1016/ 

j.sci.2023.107403. 

Intellectual Property: HHS Reference 

Number E–079–2022 includes PCT 

Patent Application No. PCT/US2023/ 

065009 filed on March 27, 2023. 

Licensing Contact: To license this 

technology, please contact Amy F. 

Petrik, Ph.D., 240–627–3721; 

amy.petrik@nih.gov, and reference E– 

079–2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2023–24551 Filed 11–6–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting 

should notify the Contact Person listed 

below in advance of the meeting. The 

meeting can be accessed from the NIH 

Videocast at the following link: http:// 

videocast.nih.gov/. 

A portion of the National Cancer 

Advisory Board meeting will be closed 

to the public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Date: February 8, 2024. 

Open: 11:00 a.m. to 1:05 p.m. 

Agenda: NCAB Subcommittee Meetings. 

Open: 1:15 p.m. to 3:30 p.m. 

Agenda: Director’s and Program reports 

and presentations; business of the Board. 

Closed: 3:30 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Bethesda, 

MD 20892 (Virtual Meeting). 


khammond on DSKJM1Z7X2PROD with NOTICES